- Execution rate: 1:1 (1 share - 1 voting right)
- Meeting time:  to be announced in the invitation letter
- Meeting venue: 10A Quang Trung Street, Ha Dong Ward, Hanoi City.
- Meeting agenda: 
+ Approval of report by the Board of Directors (BOD) on 2025 business performance and 2026 plan;
+ Approval of report by Supervisory Board (SB) on the control and verification of 2025 financial statements and 2026 plan;
+ Approval of 2025 audited financial statements;
+ Approval of the profit distribution plan;
+ Approval of 2026 remuneration plan for the BOD and SB;
+ Approval of the authorization for the BOD to select the auditing firm for 2026 and review the semi-annual financial statements;
+ Approval of the plan on issuing shares to increase charter capital from equity;
+ Electing the BOD and SB for 2026 – 2031 term;
+ Other issues within the authority of the Annual General Meeting
Coordination details and procedures for corporate action processing for holders of the above securities between VSDC, the Securities registering institution and depository members are specified in the Guideline on corporate action processing for securities holders at VSDC.
Ha Tay Pharmaceutical JSC and the parties involved in the process of preparing the dossier, documents of corporate action processing are fully responsible before the law for the legality, accuracy, truthfulness and completeness of the dossier; Institutions and individuals participating in the confirmation of records and documents shall be legally responsible within the scope related to such records and documents as prescribed in Clause 1, Article 11a of the Securities Law No. 54/2019/QH14 dated 26/11/2019, supplemented by Clause 4, Article 1 of Law No. 56/2024/QH15 dated 29/11/2024.